American Journal of Kidney Diseases
Volume 52, Issue 3 , Pages 501-506 , September 2008

Effect of Angiotensin Receptor Blockers on Cardiovascular Events in Patients Undergoing Hemodialysis: An Open-Label Randomized Controlled Trial

  • Hiromichi Suzuki, MD, PhD

      Affiliations

    • Department of Nephrology, School of Medicine, Faculty of Medicine, Saitama Medical University, Saitama, Japan
    • Corresponding Author InformationAddress correspondence to Hiromichi Suzuki, MD, PhD, Department of Nephrology, School of Medicine, Faculty of Medicine, Saitama Medical University, 38 Morohongo Moroyama, Iruma, Saitama, 350-0495 Japan
    • ,
  • Yoshihiko Kanno, MD, PhD

      Affiliations

    • Department of Nephrology, School of Medicine, Faculty of Medicine, Saitama Medical University, Saitama, Japan
    • ,
  • Soichi Sugahara, MD, PhD

      Affiliations

    • Department of Nephrology, School of Medicine, Faculty of Medicine, Saitama Medical University, Saitama, Japan
    • ,
  • Naofumi Ikeda, MD, PhD

      Affiliations

    • Department of Nephrology, School of Medicine, Faculty of Medicine, Saitama Medical University, Saitama, Japan
    • ,
  • Junko Shoda, MD, PhD

      Affiliations

    • Department of Nephrology, School of Medicine, Faculty of Medicine, Saitama Medical University, Saitama, Japan
    • ,
  • Tsuneo Takenaka, MD, PhD

      Affiliations

    • Department of Nephrology, School of Medicine, Faculty of Medicine, Saitama Medical University, Saitama, Japan
    • ,
  • Tsutomu Inoue, MD, PhD

      Affiliations

    • Department of Nephrology, School of Medicine, Faculty of Medicine, Saitama Medical University, Saitama, Japan
    • ,
  • Ryuichiro Araki, PhD

      Affiliations

    • Community Health Science Center, Saitama Medical University, Saitama, Japan

Received 12 July 2007 ,Accepted 11 April 2008.

References 

  1. Nakai S, Shinzato T, Nagura Y, et al. An overview of dialysis treatment in Japan (as of Dec. 31, 2002). J Jpn Soc Dial Ther. 2004;37:1–24
  2. Weiner DE, Tabatabai S, Tighiouart H, et al. Cardiovascular outcomes and all-cause mortality: Exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis. 2006;48:392–401
  3. Ritz E, McClellan WM. Overview: Increased cardiovascular risk in patients with minor renal dysfunction: An emerging issue with far-reaching consequences. J Am Soc Nephrol. 2004;15:513–516
  4. Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol. 2006;17:2034–2047
  5. Suzuki H. Angiotensin type 1 receptor blockers in chronic kidney disease. Contrib Nephrol. 2004;143:159–166
  6. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl. 2005;23:S9–S17
  7. Eisenberg MJ, Gioia LC. Angiotensin II receptor blockers in congestive heart failure. Cardiol Rev. 2006;14:26–34
  8. Nakamura T, Kanno Y, Takenaka T, Suzuki H. An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency. Hypertens Res. 2005;28:415–423
  9. Kanno Y, Takenaka T, Nakamura T, Suzuki H. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol. 2006;1:730–737
  10. Zannad F, Kessler M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: Results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 2006;70:1318–1324
  11. Signorini DF, Leung O, Simes RJ, Beller E, Gebski VJ. Dynamic balanced randomization for clinical trials. Stat Med. 1993;12:2343–2350
  12. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation. 2001;104:2996–3007
  13. Weber MA. Angiotensin II receptor blockers and cardiovascular outcomes: What does the future hold?. J Renin Angiotensin Aldosterone Syst. 2003;4:62–73
  14. Takahashi A, Takase H, Toriyama T, et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis—A randomized study. Nephrol Dial Transplant. 2006;21:2507–2512
  15. Zhang H, Thijs L, Staessen JA. Blood pressure lowering for primary and secondary prevention of stroke. Hypertension. 2006;48:187–195
  16. Efrati S, Zaidenstein R, Dishy V, et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis. 2002;40:1023–1029
  17. Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int. 2002;62:1020–1025
  18. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications. Kidney Int. 2005;67:799–812
  19. Suzuki H, Kanno Y, Kaneko K, et al. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. Ther Apher Dial. 2004;8:320–327
  20. Takenaka T, Kobayashi K, Suzuki H. Pulse wave velocity as an indicator of arteriosclerosis in hemodialysis patients. Atherosclerosis. 2004;176:405–409
  21. Agarwal R. Assessment of blood pressure in hemodialysis patients. Semin Dial. 2002;15:299–304
  22. Agarwal R. Systolic hypertension in hemodialysis patients. Semin Dial. 2003;16:208–213
  23. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63:793–808
  24. Mazzuchi N, Carbonell E, Fernandez-Cean J. Importance of blood pressure control in hemodialysis patient survival. Kidney Int. 2000;58:2147–2154
  25. Chae CU, Pfeffer MA, Glynn RJ, Mitchell GF, Taylor JO, Hennekens CH. Increased pulse pressure and risk of heart failure in the elderly. JAMA. 1999;281:634–639
  26. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: Prevalence, incidence, and risk factors. Diabetes Care. 2001;24:1614–1619
  27. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I Epidemiologic Follow-up Study. Arch Intern Med. 2001;161:996–1002
  28. Gilbert RE, Connelly K, Kelly DJ, Polloack CA, Krum H. Heart failure and nephropathy: Catastrophic and interrelated complications of diabetes. Clin J Am Soc Nephrol. 2006;1:193–208
  29. Khosla N, Bakris G. Lessons learned from recent hypertension trials about kidney disease. Clin J Am Soc Nephrol. 2006;1:229–235

 Originally published online as doi:10.1053/j.ajkd.2008.04.031 on July 28, 2008.

 Trial registration: http://ClinicalTrials.gov; study number: NCT00530595.

PII: S0272-6386(08)00955-4

doi: 10.1053/j.ajkd.2008.04.031

American Journal of Kidney Diseases
Volume 52, Issue 3 , Pages 501-506 , September 2008

Article Tools

* Image Usage & Resolution